Featured Research

from universities, journals, and other organizations

Nlp: all new tumor-forming protein

Date:
January 24, 2010
Source:
Journal of Clinical Investigation
Summary:
Proteins that when expressed out of context cause a cell to become cancerous are known as oncogenic proteins. Researchers have now identified in mice a new oncogenic protein that is also expressed at elevated levels in human breast cancers and lung carcinomas.

Proteins that when expressed out of context cause a cell to become cancerous are known as oncogenic proteins. Qimin Zhan and colleagues, at the Chinese Academy of Medical Sciences and Peking Union Medical College, People's Republic of China, have now identified in mice a new oncogenic protein that is also expressed at elevated levels in human breast cancers and lung carcinomas.

In the study, Nlp was found to be expressed at elevated levels in the majority of human breast and lung cancers analyzed. In the lung cancers analyzed, these high protein levels were a result of NLP gene amplification. In vitro analysis of the function of Nlp indicated that it conferred on cells tumorigenic properties, suggesting that it was an oncogenic protein. Consistent with this, mice engineered to overexpress Nlp spontaneously developed tumorigenesis in the breast, ovary, and testicle.

The authors therefore suggest that Nlp abnormalities might lead to tumor formation and development.

The research appears in the Journal of Clinical Investigation.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Shujuan Shao, Rong Liu, Yang Wang, Yongmei Song, Lihui Zuo, Liyan Xue, Ning Lu, Ning Hou, Mingrong Wang, Xiao Yang and Qimin Zhan. Centrosomal Nlp is an oncogenic protein that is gene-amplified in human tumors and causes spontaneous tumorigenesis in transgenic mice. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI39447

Cite This Page:

Journal of Clinical Investigation. "Nlp: all new tumor-forming protein." ScienceDaily. ScienceDaily, 24 January 2010. <www.sciencedaily.com/releases/2010/01/100119224924.htm>.
Journal of Clinical Investigation. (2010, January 24). Nlp: all new tumor-forming protein. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/01/100119224924.htm
Journal of Clinical Investigation. "Nlp: all new tumor-forming protein." ScienceDaily. www.sciencedaily.com/releases/2010/01/100119224924.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins